Use of EP3 Receptor Ligands to Reduce Damage from Stroke and Other Neurological Disorders

Cyclooxygenase (COX)-2 inhibitors are well known for their use as anti-inflammatory agents and have also been shown to reduce the damage associated with neuroinflammatory disorders. They act by inhibiting the production of prostaglandins, many of which mediate the inflammatory response. The effect of PGE (2) EP3 receptors on injury size was investigated following cerebral ischemia and induced excitotoxicity in mice. JHU scientists have found that stimulating the EP3 receptor with an agonist increases brain damage in mice due to excitotoxicity or ischemia-perfusion injury. Conversely, mice with a genetic deletion of the EP3 receptor had smaller regions of injury as a result of excitotoxicity than did normal mice. Together, the results suggest that the detrimental effects of COX actions are in part mediated by the EP3 receptor. Thus, the data indicate that blocking the EP3 receptor either before or after an ischemic or hypoxic event will reduce neurological-associated injury. Description (Set) Proposed Use (Set) An EP3 antagonist, that is a compound that blocks the receptor, could be given before or after an ischemic stroke to prevent and protect against the resulting brain damage.

Inventor(s): Dore, Sylvain

Type of Offer: Licensing

Next Patent »
« More Medical Patents

Share on      

CrowdSell Your Patent